Wedbush Securities’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Wedbush Securities’s Portfolio MTCR Stock Details MTCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,700	Closed	-$7K	–	1141
2023 Q1	$7K	Hold	12,700	–	–	﹤0.01%	1074
2022 Q4	$6K	Hold	12,700	–	–	﹤0.01%	1052
2022 Q3	$6K	Hold	12,700	–	–	﹤0.01%	1039
2022 Q2	$6K	Hold	12,700	–	–	﹤0.01%	1064
2022 Q1	$8K	Hold	12,700	–	–	﹤0.01%	1094
2021 Q4	$9K	Hold	12,700	–	–	﹤0.01%	1167
2021 Q3	$44K	Hold	12,700	–	–	﹤0.01%	1155
2021 Q2	$48K	Buy	+12,700	New	+$52.5K	﹤0.01%	1149

Wedbush Securities's MTCR Position: Q2 2023 in Review

Wedbush Securities sold out of Metacrine, Inc. Common Stock (MTCR) in Q2 2023, closing a stake of 12,700 shares — an estimated $7K sold.

Wedbush Securities first reported a position in MTCR in Q2 2021 and held it in 8 quarters. The position peaked at $48K in Q2 2021. 0 funds tracked by Wall St. Rank hold MTCR as of Q2 2023.

Wedbush Securities reported no remaining Metacrine, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Wedbush Securities sold 12,700 Metacrine, Inc. Common Stock shares in Q2 2023, an estimated $7K.
Wedbush Securities first reported a position in Metacrine, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Wedbush Securities's Metacrine, Inc. Common Stock position peaked at $48K in Q2 2021.
0 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q2 2023.

Based on Wedbush Securities's 13F filing for Q2 2023, filed 14 Aug 2023.